Skip to main content
. 2022 Sep 5;23(10):939–948. doi: 10.3348/kjr.2022.0115

Table 1. Baseline Characteristics.

Characteristic Total (n = 1241) Event P
Yes (n = 131) No (n = 1110)
Age, years 60.2 ± 10.4 63.3 ± 11.4 59.9 ± 10.2 0.001
Male 671 (54.1) 79 (60.3) 592 (53.3) 0.130
Body mass index, kg/m2 26.2 ± 3.6 26.2 ± 3.8 26.2 ± 3.6 0.779
Cardiac risk factors
Hypertension 824 (66.4) 92 (70.2) 732 (65.9) 0.326
Hyperlipidemia 665 (53.6) 87 (66.4) 578 (52.1) 0.002
Smoking 340 (27.4) 45 (34.4) 295 (26.6) 0.059
Family history of CAD 295 (23.8) 28 (21.4) 267 (24.1) 0.496
CCTA findings
CAD-RADS
0 190 (15.3) 5 (3.8) 185(16.7) < 0.001
1 121 (9.8) 4 (3.1) 117 (10.5) 0.006
2 502 (40.5) 41 (31.3) 461 (41.5) 0.024
3 215 (17.3) 27 (20.6) 188 (16.9) 0.293
4 189 (15.2) 49 (37.4) 140 (12.6) < 0.001
5 24 (1.9) 5 (3.8) 19 (1.7) 0.098
Leiden risk score 5.1 (1.2–11.1) 10.6 (5.1–14.6) 4.6 (1.2–10.6) < 0.001
Confirm score 13.4 (8.4–18.0) 16.5 (12.4–22.4) 12.9 (7.5–17.3) < 0.001
High-risk plaque 66 (5.3) 23 (17.6) 43 (3.9) < 0.001
Medication
Anti-platelet 480 (38.7) 45 (34.4) 435 (39.2) 0.280
Beta blocker 408 (32.9) 40 (30.5) 368 (33.2) 0.550
ACEI/ARB 287 (23.1) 35 (26.7) 252 (22.7) 0.300
Statin 482 (38.8) 64 (48.9) 418 (37.7) 0.013
Calcium channel blocker 262 (21.1) 32 (24.4) 230 (20.7) 0.330
Diabetic treatment
Diet only 248 (20.0) 22 (16.8) 226 (20.4) 0.330
Oral hypoglycemic agent 901 (72.6) 95 (72.5) 806 (72.6) 0.980
Insulin 300 (24.2) 34 (26.0) 266 (24.0) 0.610

Values are mean ± standard deviation, number of patients (%), or median (interquartile range). ACEI = angiotensin-converting enzyme inhibitors, ARB = angiotension II receptor blockers, CAD = coronary artery disease, CCTA = coronary computed tomography angiography, RADS = Reporting and Data System